Impact of ventricular assist device use on pediatric heart transplant waitlist mortality: Analysis of the scientific registry of transplant recipients database
Pediatric Transplantation · 2024-06 · 28 (4)
DOI: 10.1111/petr.14787 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Transplantation, online erschienen am 20.05.2024. Verfasst von Arene Butto und 5 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia, USA. Hauptthemen laut MEDLINE: Waiting Lists, Heart Transplantation, Heart-Assist Devices, Registries. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences.
Abstract (Originalsprache)
Background
Children awaiting heart transplant (Tx) have a high risk of death due to donor organ scarcity. Historically, ventricular assist devices (VADs) reduced waitlist mortality, prompting increased VAD use. We sought to determine whether the VAD survival benefit persists in the current era.
Methods
Using the Scientific Registry of Transplant Recipients, we identified patients listed for Tx between 3/22/2016 and 9/1/2020. We compared characteristics of VAD and non‐VAD groups at Tx listing. Cox proportional hazards models were used to identify risk factors for 1‐year waitlist mortality.
Results
Among 5054 patients, 764 (15%) had a VAD at Tx listing. The VAD group was older with more mechanical ventilation and renal impairment. Unadjusted waitlist mortality was similar between groups; the curves crossed ~90 days after listing ( p = .55). In multivariable analysis, infant age (HR 2.77, 95%CI 2.13–3.60), Black race (HR 1.57, 95%CI 1.31–1.88), congenital heart disease (HR 1.23, 95%CI 1.04–1.46), renal impairment (HR 2.67, 95%CI 2.19–3.26), inotropes (HR 1.28, 95%CI 1.09–1.52), and mechanical ventilation (HR 2.23, 95%CI 1.84–2.70) were associated with 1‐year waitlist mortality. VADs were not associated with mortality in the first 90 waitlist days but were protective for those waiting ≥90 days (HR 0.43, 95%CI 0.26–0.71).
Conclusions
In the current era, VADs reduce waitlist mortality, but only for those waitlisted ≥90 days. The differential effect by race, size, and VAD type is less clear. These findings suggest that Tx listing without VAD may be reasonable if a short waitlist time is anticipated, but VADs may benefit those expected to wait >90 days.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Cardiology, Children's Healthcare of Atlanta, Atlanta, Georgia, USA.
- Pediatric Cardiology, Nationwide Children's Hospital, Columbus, Ohio, USA.
ORCID-Profile: Arene Butto, Lydia K Wright, Jameson Dyal, Chad Y Mao, Richard Garcia, William T Mahle
Förderung
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
Zitieren
APA
Butto, A., Wright, L. K., Dyal, J., Mao, C. Y., Garcia, R., & Mahle, W. T. (2024). Impact of ventricular assist device use on pediatric heart transplant waitlist mortality: Analysis of the scientific registry of transplant recipients database. Pediatric Transplantation, 28(4). https://doi.org/10.1111/petr.14787
Vancouver
Butto A, Wright LK, Dyal J, Mao CY, Garcia R, Mahle WT. Impact of ventricular assist device use on pediatric heart transplant waitlist mortality: Analysis of the scientific registry of transplant recipients database. Pediatric Transplantation. 2024;28(4). doi:10.1111/petr.14787
BibTeX
@article{Butto2024,
author = {Butto, Arene and Wright, Lydia K and Dyal, Jameson and Mao, Chad Y and Garcia, Richard and Mahle, William T},
title = {Impact of ventricular assist device use on pediatric heart transplant waitlist mortality: Analysis of the scientific registry of transplant recipients database},
journal = {Pediatric Transplantation},
year = {2024},
volume = {28},
number = {4},
doi = {10.1111/petr.14787}
}
EUVIMED